Antiviral mechanisms of two broad-spectrum monoclonal antibodies for rabies prophylaxis and therapy.
Fc-mediated effector functions
glycoprotein
immunotherapy
monoclonal antibodies
rabies virus
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
03
2023
accepted:
17
07
2023
medline:
29
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
Rabies is an acute and lethal encephalomyelitis caused by lyssaviruses, among which rabies virus (RABV) is the most prevalent and important for public health. Although preventable through the post-exposure administration of rabies vaccine and immunoglobulins (RIGs), the disease is almost invariably fatal since the onset of clinical signs. Two human neutralizing monoclonal antibodies (mAbs), RVC20 and RVC58, have been shown to be effective in treating symptomatic rabies. To better understand how these mAbs work, we conducted structural modeling and
Identifiants
pubmed: 37638057
doi: 10.3389/fimmu.2023.1186063
pmc: PMC10449259
doi:
Substances chimiques
Antiviral Agents
0
Rabies Vaccines
0
Antibodies, Monoclonal
0
Broadly Neutralizing Antibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1186063Informations de copyright
Copyright © 2023 Zorzan, Castellan, Gasparotto, Dias de Melo, Zecchin, Leopardi, Chen, Rosato, Angelini, Bourhy, Corti, Cendron and De Benedictis.
Déclaration de conflit d'intérêts
Authors GDM, HB and DC hold a patent for some of the mAbs described in the present review PCT/EP2019/078439. Authors AC and DC are employees of the company Vir Biotechnology Inc. and may hold shares in Vir Biotechnology Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Bioessays. 1997 Nov;19(11):993-1000
pubmed: 9394621
PLoS One. 2021 Sep 1;16(9):e0256779
pubmed: 34469480
PLoS Negl Trop Dis. 2015 Apr 16;9(4):e0003709
pubmed: 25881058
J Chem Phys. 2008 Sep 21;129(11):114101
pubmed: 19044944
Curr Opin Virol. 2019 Apr;35:1-13
pubmed: 30753961
Curr Opin Virol. 2017 Jun;24:60-69
pubmed: 28527859
Vaccine. 2019 Oct 3;37 Suppl 1:A132-A139
pubmed: 30503659
Neurosci Lett. 2009 Oct 16;464(1):29-33
pubmed: 19679164
Vaccine. 2007 Apr 12;25(15):2800-10
pubmed: 17240489
Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11300-5
pubmed: 19581599
Antiviral Res. 2015 Sep;121:9-15
pubmed: 26093157
Nat Rev Neurol. 2020 Nov;16(11):601-617
pubmed: 33005040
Cell Host Microbe. 2022 Sep 14;30(9):1219-1230.e7
pubmed: 35985336
J Phys Chem B. 2010 Feb 4;114(4):1652-60
pubmed: 20055378
Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7252-6
pubmed: 1496020
Vaccine. 2018 Sep 5;36(37):5500-5503
pubmed: 30107991
J Virol. 1998 Jan;72(1):273-8
pubmed: 9420224
Cell. 2021 Aug 19;184(17):4593-4595
pubmed: 34416148
PLoS Pathog. 2009 May;5(5):e1000453
pubmed: 19478866
J Virol. 2001 Nov;75(21):10208-18
pubmed: 11581389
Virology. 1995 Oct 1;212(2):411-21
pubmed: 7571410
Cell. 2016 Jul 28;166(3):596-608
pubmed: 27453466
Science. 2009 Apr 10;324(5924):246-51
pubmed: 19251591
Virology. 2002 Mar 1;294(1):70-4
pubmed: 11886266
J Virol. 2012 Dec;86(24):13467-74
pubmed: 23035224
Arch Virol. 2017 Nov;162(11):3251-3268
pubmed: 28726129
J Virol. 2015 Dec;89(23):12084-95
pubmed: 26401034
Vaccine. 2008 Nov 5;26(47):5922-7
pubmed: 18804136
Clin Infect Dis. 2018 Jan 18;66(3):387-395
pubmed: 29020321
Vaccine. 2022 Oct 6;40(42):6153-6162
pubmed: 36123259
Cell Mol Immunol. 2021 Feb;18(2):250-258
pubmed: 33437050
J Clin Invest. 2014 Mar;124(3):1187-98
pubmed: 24569373
Cell Host Microbe. 2020 Mar 11;27(3):441-453.e7
pubmed: 32004500
J Virol. 2008 Jun;82(12):5750-60
pubmed: 18417595
EMBO Mol Med. 2020 Nov 6;12(11):e12628
pubmed: 32945125
Nat Commun. 2020 Jan 30;11(1):596
pubmed: 32001700
Travel Med Infect Dis. 2022 Mar-Apr;46:102267
pubmed: 35091118
Viruses. 2021 Nov 16;13(11):
pubmed: 34835093
Front Mol Biosci. 2021 Jul 28;8:729513
pubmed: 34395534
Viruses. 2021 Nov 25;13(12):
pubmed: 34960633
Sci Adv. 2022 Jun 17;8(24):eabp9151
pubmed: 35714192
J Mol Biol. 2016 Feb 22;428(4):720-725
pubmed: 26410586
EMBO Mol Med. 2016 Mar 31;8(4):407-21
pubmed: 26992832
Science. 2021 Sep 03;373(6559):1109-1116
pubmed: 34344823
J Virol. 1985 Mar;53(3):926-34
pubmed: 2579247
PLoS One. 2011 May 09;6(5):e19848
pubmed: 21573024
Proteins. 2009 Feb 1;74(2):497-514
pubmed: 19062174
Trends Microbiol. 1993 May;1(2):63-6
pubmed: 8044464
EMBO J. 1998 Dec 15;17(24):7250-9
pubmed: 9857182
Cell Rep. 2019 Jan 8;26(2):438-446.e5
pubmed: 30625326
Bing Du Xue Bao. 2016 Jul;32(4):399-403
pubmed: 29979531
mSphere. 2019 May 22;4(3):
pubmed: 31118297
Bioinformatics. 2006 Jan 15;22(2):195-201
pubmed: 16301204
Curr Opin Virol. 2022 Apr;53:101204
pubmed: 35151116
Annu Rev Immunol. 2013;31:705-42
pubmed: 23330954
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W252-8
pubmed: 24782522
N Engl J Med. 2005 Jun 16;352(24):2508-14
pubmed: 15958806
J Virol. 2010 Sep;84(17):8926-36
pubmed: 20538851
Front Cell Infect Microbiol. 2021 Nov 05;11:761074
pubmed: 34804996
Emerg Microbes Infect. 2019;8(1):1721-1733
pubmed: 31769733
J Mol Biol. 1998 Aug 7;281(1):95-106
pubmed: 9680478
Sci Rep. 2017 Feb 06;7:41889
pubmed: 28165503
Int J Mol Sci. 2020 Jan 13;21(2):
pubmed: 31941161
Science. 2016 Aug 19;353(6301):823-6
pubmed: 27417494
Viral Immunol. 2000;13(1):83-92
pubmed: 10733171
Cell. 1996 Mar 22;84(6):941-51
pubmed: 8601317
PLoS Negl Trop Dis. 2017 Dec 20;11(12):e0006133
pubmed: 29261658
Immunology. 1987 Jan;60(1):75-82
pubmed: 3028937
Cell Host Microbe. 2018 Sep 12;24(3):417-428.e5
pubmed: 30146390
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12400-4
pubmed: 16895988
Virus Res. 2004 Dec;106(2):117-32
pubmed: 15567492